Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
Biofrontera Inc. Warrants logo

NASDAQ · BFRIW

Biofrontera Inc. Warrants

Healthcare · Drug Manufacturers - Specialty & Generic

$0.01

Down-$0.00 (-20.00%)

Updated Oct 10, 2026, 3:21 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
815.95K
P/E ratio
-0.45
Dividend yield
0.00%
52-week range
$0.01 – $0.28
Volume
5.29K
Avg. volume
8.86K

Price performance · BFRIW

BFRIW price history

1M range · 15 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

BFRIW closed at $0.01 after 15 trading sessions, down 72.00% for the selected period.

Last close
$0.01
Period change
-72.00%
Period low
$0.01
Period high
$0.02
Daily close
View OHLC price history
BFRIW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$0.008$0.008$0.0056$0.00565.29K
Oct 8, 2026$0.009$0.009$0.007$0.0072.01K
Oct 7, 2026$0.0052$0.0109$0.0052$0.0109778
Oct 6, 2026$0.0138$0.0138$0.0138$0.0138209
Oct 5, 2026$0.0148$0.0148$0.0148$0.0148281
Oct 2, 2026$0.015$0.015$0.015$0.015116
Sep 30, 2026$0.0098$0.014$0.0098$0.009813.93K
Sep 29, 2026$0.015$0.015$0.015$0.0151.35K
Sep 28, 2026$0.0135$0.0135$0.0135$0.0135196
Sep 25, 2026$0.02$0.02$0.02$0.025.03K
Sep 24, 2026$0.02$0.0201$0.02$0.0201811
Sep 23, 2026$0.0203$0.0203$0.02$0.023.05K
Sep 16, 2026$0.0206$0.0206$0.0203$0.02063.67K
Sep 15, 2026$0.0206$0.0206$0.0203$0.0203264
Sep 11, 2026$0.0205$0.0206$0.02$0.025.26K

Latest BFRIW news

The latest Smart Investors Daily articles mentioning BFRIW.

Stock researchCompany · Overview

BFRIW research

Overview

Company profile and research snapshot.

Company profile

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 14, 2026

Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma

Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform WOBURN, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announce

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By